MDxHealth is a molecular diagnostics company focused on improving the detection and risk stratification of cancer through non-invasive testing. The firm develops and commercializes proprietary biomarker assays that analyze gene expression and epigenetic changes to guide clinical decision-making, with a particular emphasis on prostate cancer. By offering actionable insights into disease likelihood and aggressiveness, MDxHealth’s solutions aim to reduce unnecessary biopsies and enable more personalized patient management strategies.
Among its core offerings are SelectMDx, a urine-based test that evaluates the expression levels of mRNA biomarkers associated with the presence of high-grade prostate cancer, and ConfirmMDx, a tissue-based epigenetic assay designed to detect field effects in ostensibly negative prostate biopsies. These tests are supported by robust clinical validation studies and are intended to complement standard diagnostic workflows, helping physicians identify patients at higher risk who may benefit from further investigation.
Headquartered in Belgium, MDxHealth also maintains a CLIA-certified laboratory in the United States and collaborates with leading commercial and academic laboratories across North America and Europe. The company’s global footprint is supported by dedicated commercial teams and strategic partnerships, enabling broad access to its diagnostic tests in key markets where prostate cancer screening and management are priority areas.
Founded in 2007 as a spin-off from academic research in molecular oncology, MDxHealth went public on Euronext Brussels in 2015 and trades in the U.S. as an over-the-counter equity. The company’s management team brings together expertise in biotechnology, molecular diagnostics and regulatory affairs, underscoring its commitment to advancing precision diagnostics for improved patient outcomes.
AI Generated. May Contain Errors.
